Compare Adaptive Biotechnologies Corp (ADPT) vs Lam Research Corporation (LRCX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Lam Research Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Lam Research Corporation trades at $335.5 (market cap $407.85B). The key difference: Lam Research Corporation is far larger — about 122.5× Adaptive Biotechnologies Corp's market cap, and Lam Research Corporation pays a 0.32% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LRCX | |
|---|---|---|
Market Cap | $3.33B | $407.85B |
Sector | Health | Technology |
52-Week High | $22.37 | $433.33 |
52-Week Low | $10.24 | $94.84 |
Enterprise Value | $3.19B | $406.83B |
Dividend Yield | — | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Lam Research (LRCX) trades at $326.13, down 7.19% amid a broader chip stock sell-off, yet maintains a bullish technical signal with strong support at $323. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.47 exceeding expectations, and demonstrates solid fundamentals including a 30.94% net income margin and positive cash flow trends. Analyst sentiment remains overwhelmingly positive with a $378 consensus price target.
LRCX's outlook is supported by AI-driven demand for semiconductor equipment, though valuation multiples appear elevated. Key risks include sector volatility and competitive pressures, but institutional bullishness and consistent execution provide a favorable backdrop for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
